- Sana Biotechnology, a gene engineering firm, debuted on the Nasdaq market under the ticker SANA.
- The company offered 23.5 million common share at $25 per share, with gross proceeds expected to be $587.5 million.
- Morgan Stanley, Goldman Sachs, JP Morgan Securities and BofA Securities acted as the underwriters for the IPO.
- The IPO was the largest ever for a preclinical biotech company.
Chynna Lewis - Researcher